CHA Biotech, a leading biopharmaceutical company, was established in Sept. 2000 by CHA Medical Group to create a central, multidisciplinary research facility where the university’s scientists and hospital physicians could come together and focus their efforts on developing stem cell, gene therapy and regenerative medicine technology.
CHA Biotech headquartered in South Korea with R&D focus in stem cells, and cell therapeutics.
The company is a member of CHA Medical Group, which comprise of medical university, medical centers and hospitals located in the US and Korea with in excess of two thousand five hundred beds under care, fertility centers, stem cell research and development centers, personal & preventive medicine and bio venture divisions.
CHA Biotech has the greatest number of stem cell R&D pipelines in therapeutic areas including Stargardt's Degeneration, Age-related Macular Degeneration, Intermittent Caludication, Stroke, Alzheimer Disease, and Disk Degeneration. Some are in early stages and some are in mid to late development stages.
The Company also successfully operates a cord blood banking business (i-Cord), stem cell banking business (Bio Insurance), and a non-medical business of CHAUM.
As part of its global business strategy, CHA Biotech expanded its operations to the United States in 2002 with the opening of CHA Fertility Center (CFC) in Los Angeles followed by the 2005 acquisition of Hollywood Presbyterian Medical Center (HPMC), a 434-bed general, acute-care hospital also located in LA.
Currently, CHA Healthcare (a subsidiary of CHA Biotech) operates CFC and HPMC.
With seasoned experience and research infra structure, CHA Biotech has built up multiple strategic relations with major research institutions in the field of stem cell research and infertility areas. The company is listed in Korean stock market and it currently has 7 subsidiary companies in Korea and 2 subsidary companies in the United States.